MEK5/ERK5/mef2: A novel signaling pathway affected by hepatitis C virus non-enveloped capsid-like particles  by Katsarou, Konstantina et al.
Biochimica et Biophysica Acta 1813 (2011) 1854–1862
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamcrMEK5/ERK5/mef2: A novel signaling pathway affected by hepatitis C virus
non-enveloped capsid-like particles
Konstantina Katsarou a, Panagiota Tsitoura b, Urania Georgopoulou a,⁎
a Molecular Virology Laboratory, Hellenic Pasteur Institute, Greece
b Insect Molecular Genetics and Biotechnology Group, Institute of Biology, NCSR Demokritos, GreeceAbbreviations: HCVne, Hepatitis C non-envelope
epidermal growth factor; MAPKs, Mitogen Activated Pro
inhibitor of both MEK1 and MEK2; PD98059, Speciﬁc
mitogen-activated protein kinase kinase (MAPKK); EEA
fra-1, fos-related antigen 1
⁎ Corresponding author. Tel.: +30 2106478876.
E-mail address: uraniag@pasteur.gr (U. Georgopoulo
0167-4889/$ – see front matter © 2011 Elsevier B.V. A
doi:10.1016/j.bbamcr.2011.06.015a b s t r a c ta r t i c l e i n f oArticle history:
Received 9 March 2011
Received in revised form 24 June 2011
Accepted 27 June 2011
Available online 8 July 2011
Keywords:
Hepatitis C virus
Non-enveloped capsid-like particle (HCVne)
ERK5
mef2
Cell signalingHepatitis C virus (HCV) is an RNA positive strand virus, member of the Flaviviridae family. The viral particle is
composed of a capsid containing the genome, surrounded by E1 and E2 proteins, however different forms of
viral particles have been observed including non-enveloped particles. Previous reports have proposed that
hepatitis C non-enveloped capsid-like particles (HCVne) enter cells of hepatic origin via clathrin-mediated
endocytosis, during which different signaling events occur. In this report we show that HCVne particles are
capable of inducing the recently discovered ERK5 pathway, in a dose dependent way. The ERK5 pathway can
be activated by growth factors and other extracellular signals. This speciﬁc activation occurs through a well
characterized upstream kinase, MEK5, and is capable of inducing gene regulation of mef2. In contrast, when
HCV core structural and NS5A non-structural proteins were expressed endogenously no activation of this
pathway was detected. These cell signaling events could be of critical importance and might give clues for the
elucidation of cellular manifestations associated with HCV infection.d capsid-like particles; EGF,
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An estimated 3% of theworld's population is infected by hepatitis C
(HCV), an enveloped positive-strand RNA virus, with a genome of
approximately 9600 nucleotides, encoding structural (Core, E1, E2),
p7 and six non-structural (NS2, NS3, NS4A, NS4B, NS5A, NS5B)
proteins [1–3]. In most infected individuals, this virus evades the
immune system and establishes a chronic infection that can lead to
cirrhosis, liver cancer and death [4,5]. The HCV virion nucleocapsid is
surrounded by a lipid layer containing glycoproteins E1 and E2 [1–3].
However, different forms of HCV particles are present in the
circulation of infected individuals, among them are naked capsids
[6–8], capable of entering cells and causing signaling events [9–11]. In
this study we investigate the interplay of the HCV core and NS5A
proteins as well as non-enveloped capsid-like particles (HCVne) with
the MAPK (mitogen-activated protein kinases)–ERK5 pathway. ERK5
(extracellular signal-regulated protein kinase 5), also known as BMK1
(Big Mitogen Kinase 1), is a MAPK showing 80% similarity with ERK1/2
proteins [12]. This kinase contains the typical ERK phosphorylation
motif (TEY) and a unique C-terminal region believed to be responsiblefor its distinct biological activities [13]. Its activity is increased in
response to growth factors, oxidative stress and hyperosmolarity, via
a direct phosphorylation by MEK5 [14]. It is important to note that
ERK5 has been implicated in different types of cancers as well as in
angiogenesis, probably due to the proven activation of the Ras/Raf
pathway [15,16]. Until now no information about the involvement of
this pathway in HCV infection has been reported. Data in this study
suggested that the MEK5–ERK5 pathway can be activated by HCVne
but not by endogenously expressed core orNS5Aproteins. Furthermore,
we provide evidence that this pathway can induce MEF2 activation, a
well known downstream target of the pathway.
2. Materials and methods
2.1. Plasmids
The HCV genotype 1a (H) [17] was used to generate the plasmid
constructs of this study. Core sequence was digested out as an NdeI
fragment from plasmid pHPI 1327 [11] and inserted into the SmaI site
of pCI plasmid (Promega) generating plasmid pHPI 1430. Plasmid
pHPI 1404 producing NS5A protein has been described previously
[18]. Plasmids pHPI 1319 [11] (full-length core C191), pHPI 1558
(P. Tsitoura unpublished) (truncated core form C179), and plasmid
pET-9d-GFP [19] were used for production of soluble proteins. For the
construction of a baculovirus expressing core protein under a CMV
promoter, an NdeI fragment from pHPI 1327 plasmid was introduced
to StuI-digested pRB5850 plasmid, kindly provided by Dr. B. Roizman
yielding pHPI 1488. For construction of NS5A expressing baculovirus,
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(unpublished data). MEF2A-LUC was a gift from Dr. S. Khochbin [20].
MEK5WT, MEK5AA and MEK5DD were from Dr. J.D. Lee [21]. Plasmid
pCI ERK5FLwasa gift fromDr.A.Winoto [16]. ThepSirenERK5wasagift
from Dr. M.Villalba [66] and GFP-Rab5WT and GFP-Rab5S34N were a
gift from Dr. Juan S. Bonifacino [22].
2.2. Cells and reagents
HepG2 (human hepatocellular liver carcinoma cell line) and
Spodoptera frugiperda Sf9 cells were purchased from ATCC. Huh-7
(human hepatoma) cells were kindly provided by Dr. R. Bartenschlager
(University of Heidelberg, Germany). The following antibodies were
used: rabbit anti-ERK5 (Sigma), rabbit anti-phospho-p44/42 (Cell
Signaling), rabbit anti-ERK1 (Santa Cruz), mouse anti-EE autoantigen
1 (EEA1) (BD Biosciences), mouse anti-actin (Chemicon), rabbit and
mouseAlexa−488,−546 (Molecular Probes), rabbit anti-core [11], and
rabbit anti-NS5A [23]. Protein-A agarose was from Santa Cruz,
recombinant human EGF from R&D, and inhibitors UO126–PD98059
from Cell Signaling.
2.3. Cell culture, transient transfection and Western blotting
Cells were grown in Dulbecco Modiﬁed Eagle Medium (DMEM)
containing a low glucose concentration (1000 mg/l) and antibiotics
(penicillin at 100 U/ml, streptomycin at 100 μg/ml) and supplemented
with 10% Fetal Calf Serum (FCS). Transient transfection of expression
plasmidswas performedwith JetPEI reagent (PolyPlus) according to the
manufacturer's protocol. Cells were lysed in ice-cold lysis buffer [1%
Triton X-100, 50 mM KCl, 10 mM Tris pH 7.5, 1 mM DTT, 2 mM MgCl2,
complete-mini protease inhibitor cocktail tablets (Roche), 1 mM PMSF,
2 mM sodium orthovanadate], electrophoretically separated on 6, 8 or
10% SDS-gels, transferred onto nitrocellulose membranes, incubated
with appropriate antibodies and detected by enhanced chemilumines-
cence (Pierce). Quantity One 4.4.1 software (Bio-Rad) was used for gel
band quantiﬁcation. Immunoprecipitationwas performed as previously
described [18]. For co-immunoprecipitation, lysates from HepG2
transfected cells (0.5 ug plasmid DNA/well) were further diluted
ﬁvefold in RIPA buffer (50 mM Tris-cl pH 7.4, 150 mM NaCl, 1% NP40,
0.25% Na-deoxycholate, 1 mM PMSF, 1× Roche complete mini protease
inhibitor cocktail, 1× Roche PhosSTOP Phosphatase Inhibitor cocktail)
and incubated on a rotary shaker at 4 °C overnight, with antibody
against ERK5 (Sigma). Resulting complexes were precipitated with
protein A-agarose beads (Santa Cruz), followed by three washes with
lysis buffer, separated on 8% SDS-polyacrylamide, transferred onto
nitrocellulose membranes and ﬁnally blotted with ERK5 antibody. For
luciferase assays, HepG2 cells were transfected as previously described.
Twenty-four hours post transfection cells were starved by incubation
with DMEM without FCS for 8 to 12 h and then HCVne particles
(corresponding to approximately 5 ng of core protein) were added for
18 h. A similar protocol was followed for the controls. Cell extracts were
prepared and luciferase assays were performed using the Luciferase
Assay System (Promega) according to the manufacturer's instructions.
The reaction was performed andmeasured in a luminometer GloMax™
20/20 (Promega). The protein concentration was determined with a
protein assay kit (Bio-Rad) and used for normalization of the luciferase
assays. All experiments were repeated at least eight times in duplicates
or triplicates including all necessary controls, and resultswere analyzed
using the Student t-test. The level of signiﬁcance was set as Pb0. 05 (*),
Pb0. 01 (**), Pb0.001 (***).
2.4. Baculovirus expression system
The S. frugiperda Sf9 cell line was used for the generation and
propagation of the recombinant baculoviruses Bac1488 and Bac8119
(P. Tsitoura and A. Kakkanas, unpublished data). Cells weremaintained in Sf900II SFM (Gibco) medium supplemented with 5%
fetal bovine serum at 27 °C. Generation of recombinant baculoviruses
was performed according to standard protocols using Baculogold
linearized DNA (BD Biosciences) and propagation of viruses was
performed in 5% Sf900II medium supplemented with 50 μg/ml
gentamycin (Gibco) [11]. A control GFP virus (Bac 1746) was also
produced [10].
For baculovirus transduction of mammalian cells, HepG2 cells at a
density of 5×105 were infected with an MOI of 50 for 3 h at room
temperature. Following infection, 5 mM of sodium butyrate was
added in the medium for 24 h. After 48 h of infection, cells were lysed
as described previously.
2.5. Generation of cell lines expressing HCV core protein
HepG2 Tet-on stable cell lines (Clontech) expressing the core
protein were generated as follows: cloning of the core (aa: 1–191)
coding sequence from pHPI 1327 into the EcoRI site of pTRE
expression vector (Clontech) yielded pHPI 1489. Plasmid pHPI 1489
was electrotransfected in HepG2 Tet-on cells that were grown in
presence of 100 μg/ml G418. Transfected cells were selected by
addition of 200 μg/ml hygromycin and individual clones were
obtained by limited dilution. Induction in HepG2 Tet-on core cell
lines was performed by addition of 10 ug/ml doxycycline for 24–48 h.
2.6. Production of HCV non enveloped capsids (HCVne) and soluble core
protein
The capsid-like particles were isolated from cell lysates, as
previously described [9–11,24]. Brieﬂy, fractions (650 μl each) were
collected from the top of the sucrose gradient, the density was
determined by refractometry. HCV core antigen in collected fractions
[11] and cell lysates expressing core protein was estimated both with
the Ortho HCV core antigen ELISA test system (Ortho-Clinical
Diagnostics) using serial dilutions of a puriﬁed recombinant core
protein as standard curve, and by densitometric analysis of band
intensities from a single ﬁlm obtained after SDS-PAGE followed by
immunoblotting. Expression and puriﬁcation of soluble proteins have
already been described [11].
2.7. Immunoﬂuorescence staining
Following addition of HCVne, corresponding to 10 ng of core
protein, at the indicated time cells grown on coverslips were washed
three times with phosphate-buffered saline (PBS), ﬁxed with 4% (w/
v) paraformaldehyde in PBS (30 min) and the remaining reactive
groups were blocked with 100 mM glycine. Cells were permeabilized
with 0.02% (v/v) Triton X-100, and incubated with the appropriate
primary and secondary antibodies for 45 min respectively. Slides were
examined using a Leica TCS-SP5 confocal microscope. Sequential
scanning between channels was used to separate ﬂuorescence
emission from different ﬂuorochromes and to completely eliminate
bleed-through between channels. Typically, nine to ﬁfteen confocal
sections from three to ﬁve independent experiments, were quantiﬁed
for co-localization of core and EEA1 puncta using the co-localization
function in Image-Pro Plus software (Media Cybernetics). A similar
approach has been used to quantify the co-localization of other
proteins as described previously [9].
3. Results
3.1. Potency of endogenously expressed HCV core and NS5A proteins to
activate the ERK5 pathway
ERK5 is amember of MAPK that has been found in a phosphorylated
state in cancers of different origins including liver cancer [12,15,16,25].
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of infection [4,26]. Therefore, the ability of two HCV proteins, known
to interact with different signaling pathways, was tested for ERK5
activation. Numerous antibodies exist that are purported to be speciﬁc
for the phosphorylated ERK5 protein, howeverwe have not found these
reagents to react satisfactory under our experimental conditions.
Thus, we have used the migrational shift seen on polyacrylamide
gels of phosphorylated forms of proteins to determine whether
phosphorylation has occurred. At the time this study was initiated,
no positive control for ERK5 pathway in cells of hepatic origin existed,
therefore epidermal growth factor (EGF), serum and insulin were
tested and EGF was retained as positive control throughout this study
(Fig. 1B).
Transfections with plasmids expressing one structural, core, as
well as one non-structural HCV protein, NS5A (Fig. 1A), were
performed and endogenous ERK5 expression was investigated.
Based on our results, neither expression of core nor NS5A proteins
when expressed were able to activate ERK5 (Fig. 2A). To further
conﬁrm the absence of band shifting, immunoprecipitation experi-
ments with ERK5 antibody were developed by using cell lysates
transfected with the same expression plasmids (core and NS5A)
followed by immunodetection with the same antibody (Fig. 2C). In
addition, cell transduction with baculoviruses expressing core
(Bac1488) or NS5A (Bac 8119) was performed (Fig. 2B). Furthermore,
an inducible HepG2 Tet-on cell line expressing core protein in the
presence of doxycycline (Fig. 2D) was tested. In all these cases no
ERK5 phosphorylation was observed, suggesting that these proteins
even when intracellularly expressed at a high level, are not able to
activate the pathway.
3.2. ERK5 pathway activation by HCVne particles
Previously published results suggested that HCV nucleocap-
sids without a lipid envelope circulate in the serum of HCV in-
fected patients [6–8,27]. As previously described [9–11] we were able
to generate non-enveloped core capsids (HCVne) – using the
baculovirus expression system producing structural core protein –
that are endocytosed in a clathrin-dependent way during which the
ERK1/2 pathway can be activated, thus producing immediate early
genes activation [9]. To test if the ERK5 pathway can also be activated
by these capsids, HepG2 cells were challenged with HCVne. A ﬁvefold
activation was observed after 30 min of incubation at 37 °C (Fig. 3A).
Similar activation was also observed in Huh7 (Fig. 3B) as well as in
human brain cells SK-N-SH (data not shown) although a difference in
the fold of activation was observed. As controls, we used either a
fraction of the same sucrose density from infected Sf9 cells with
Bac1746— a control baculovirus expressing GFP [10] (Fig. 3C) or heat-191
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cells treated with EGF (50 nM), insulin (4.5 mM) and fetal calf serum (30%) were elect
Endogenous ERK5 expression of phosphorylated and non-phosphorylated forms is indicatedenatured HCVne particles (treated for 1 h at 100 °C) (Fig. 3D) as well
as 60% sucrose (data not shown). In all these cases no ERK5 activation
was observed. Speciﬁcity of this phenomenon was further proved by
investigating the correlation of increasing HCVne particles concen-
tration with increasing ERK5 phosphorylation (Fig. 3E). It is also
important to mention that when soluble core protein, (1–191aa) or
truncated (1–179aa), or GFP, all of bacterial origin were used
exogenously in the same cells no ERK5 activation was observed
(Fig. 3F). The same result was observed when very high concentra-
tions of bacterial core protein (1–191aa) were used (Fig. 3G). This
ﬁnding allowed us to insinuate that it is the particulate form of the
capsid and not the protein per se that is responsible for this
phenomenon.3.3. ERK5 activation by HCVne particles probably occurs through MEK5
Up until now, in the absence of broadly accepted selective
inhibitors of ERK5, the most commonly used inhibitors to block the
ERK5 pathway are MEK1/2 inhibitors UO126 and PD98059 [28], but
with ambiguous and often cell type speciﬁc results. Their precise
mechanism of action on MEK5 remains unknown.
We have observed an inhibition of ERK1/2 activation but no effect
on ERK5 phosphorylation (data not shown) by using different
concentrations of these inhibitors at low concentrations. In contrast,
at high concentrations (20 μΜ) and increased pre-treatment time
(3 h), UO126 inhibitorwas able to block the pathway after stimulation
with EGF as well as after 30 min of incubation with HCVne (Fig. 4A).
Previous studies [9] have shown that HCVne particles entered cells in
a clathrin and pH dependent endocytosis, “traveling” from early to
late endosomes and ﬁnally reaching lysosomes. To eliminate the
possibility that the loss of ERK5 signal was produced by decrease of
binding and entry of HCVne particles, we investigated the capacity of
these particles to enter Huh7 cells. Cells were pretreated with UO126
inhibitor (20 μΜ–3 h) and particles were added for 30 min at 37 °C,
prior to ﬁxation and labeling for core and EEA1 (a speciﬁc endosomal
marker) antigens. At this time point we have previously observed
induced phosphorylation of ERK5 (Fig. 1B) and as already reported a
number of uptaken HCVne were still present in early endosomes
although the maximum co-localization was evaluated at 15 min post-
binding/uptake [9]. Subsequently cells were visualized using confocal
microscopy and ﬁfteen confocal sections from three independent
experiments were analyzed for colocalization with the specialized
co-localization function of the Image-Pro Plus software. As shown in
Fig. 4B e, f and g, no differences in rate of endocytosis rate between
inhibitor treated and non-treated cells – both incubated with HCVne –
were observed.NS4B NS5A NS5BA
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PD98059 inhibitor was not able to block ERK5 phosphorylation,
although it blocked very efﬁciently the ERK1/2 pathway activation
(Fig. 4C). The difference observed with these two inhibitors was
probably due to the efﬁcacy or mechanism of action of each agent.
Minimal cell toxicity was observed in drug-treated cells through the
spectra of concentration used in this experiment (data not shown).
Moreover, in HepG2 cells transfected with pSIREN shERK5
plasmid, a considerable silencing of ERK5 expression accompanied
by reduced phosphorylation was observed compared to cells treated
with the control vector, after incubation with HCVne for 30 min at
37 °C (Fig. 4Da and d) indicating the speciﬁcity of the cell signaling
phenomena observed. Additionally, in the same lysates the ERK1/2
expression was not affected (Fig. 4b, c and d).Taken together these data suggested that ERK5 activation by
HCVne particles probably occurs through MEK5, although a possible
alternative route affecting this kinase activation cannot be excluded.
3.4. ERK5 phosphorylation is followed by mef2 activation
Stimulation of MAPK pathway is followed by transcriptional
promoter activation. The ERK5 pathway has been implicated in the
activation of different genes, like c-fos, fra-1 and c-jun, although with
conﬂicting results, probably due to tissue speciﬁcity [29,30]. The most
commonly activated promoter elements downstream of ERK5, in a
great number of studies, ismef2 (myocyte enhancer factor-2) [31–34].
Therefore, we used plasmid containing mef2A promoter elements
fused to the coding sequences of luciferase gene. As shown in Fig. 5A,
1859K. Katsarou et al. / Biochimica et Biophysica Acta 1813 (2011) 1854–1862an important up-regulation of luciferase activity was observed with
mef2A plasmid following incubation of the transfected cells with
HCVne particles compared to the heat-denatured particles. The
response was entirely abolished at higher concentrations (20 μΜ) of
MEK inhibitor UO126, showing that the observed up regulated signal
was MEK5–ERK5 dependent. To further support the involvement of
the pathway inmef2 activation, HepG2 cells were co-transfected with
mef2A plasmid andMEK5WT or a dominant negative mutant plasmid:
MEK5AA, containing mutations in Ser311 and Thr315 blocking the
phosphorylation of the protein and thus of ERK5 protein plasmids.
Luciferase rates were measured as described before. As shown in
Fig. 5B, the increase in mef2A luciferase levels due to HCVne particles
is not observed when this MEK5 mutant was used, supporting the
notion that mef2A activation is suggested to be MEK5 dependent.
3.5. MEK5–ERK5–mef2 modulation is HCVne endocytosis-dependent
As previously reported HCVne particles are clathrin-mediated
endocytosed in cells of hepatic origin [9]. In order to understand if
ERK5 up regulation was linked to endocytosis of HCVne, cells of
hepatic origin were co-transfected with mef2A plasmid, MEK5WT or
MEK5AA or MEK5DD (constitutively active) and either GFP-Rab5WT
or GFP-Rab5S34N. Rab5S34N is a dominant negative GDP-binding
mutant shown to reduce endocytosis of different ligands. The activity
ofmef2A-luc in cells co-expressingMEK5WT and Rab5WTwas used as
control. As demonstrated in Fig. 6A we observed that mef2a-luc
activity was signiﬁcantly reduced when MEK5WT was co-expressed
with Rab5S34N, compared to the Rab5WT, indicating that this
activation was sensitive to endocytosis of HCVne particles. This result
was further conﬁrmed by endogenous mef2A mRNA levels (Fig. 6B).
Furthermore an important downregulation was observed when
expression of Rab5WT was performed in the presence of MEK5AA
andwas almost recovered in the presence of MEK5DD (Fig. 6A). Taken
together, these results suggested that HCVne particles are capable ofB
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and incubated or not with HCVne particles or with controls (same fraction heat denatured
Treatment with UO126 was performed at 20 μM. B) HepG2 cells were transfected withmef2A
and incubated or not with HCVne particles or with controls (same fraction heat denatured
protein amount. Fold activation values were calculated relative to the levels of luciferase ac
independent experiments performed in triplicates for Fig. 5A and in duplicates for Fig. 5B wactivating the MEK5–ERK5–mef2 pathway when endocytosed in cells
of hepatic origin.
3.6. ERK5 localization
The mechanisms that govern the subcellular distribution of ERK5
are largely unknown and various apparent discrepancies exist
probably due to cell type. The C-terminal region of the ERK5 protein
contains an active NLS (nuclear localization signal) and a NES (nuclear
export signal), transforming the protein into a ‘moving’ cytoplasmic-
nuclear protein [35]. Therefore, several reports indicated that
analogously to ERK1/2, ERK5 is a cytoplasmic protein that moves to
the nucleus upon growth factor stimulation [33,36]. However, other
data have indicated that ERK5 may reside in the nucleus of HeLa or
Rat-1, independently on their stimulation with growth factors [37].
Huh7 starved cells were treated with HCVne for 30 min.
Fluorescence confocal microscopy visualization revealed a cytoplas-
mic localization of endogenous ERK5 in resting cells that relocates to
the nucleus after stimulation with EGF (Fig. 7A, B) supporting
previous data for translocation of ERK5 to the nucleus after activation.
In contrast, incubation with HCVne produced a perinuclear and in a
few cases a nuclear distribution of ERK5 (Fig. 7C).
4. Discussion
Mitogen-activated protein kinases (MAPKs) are highly conserved
molecules that transduce extracellular stimuli into intracellular
responses in different organisms [38,39]. While other MAPKmembers
are well characterized, ERK5 constitutes a relatively new kinase
(discovered in 1995) that has not been fully investigated [12,38–41].
The physiological function of ERK5 signaling is just beginning to be
elucidated. Growth factor activation of ERK5 in nonneuronal cells has
been implicated in ﬁbroblast cell proliferation, muscle cell differen-
tiation, and cancer cell transformation [21,42–44]. Different stimuliMEK5AA MEK5AA+HCVne
+HCVne
atured
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*
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) for 18 h. Transfected cells treated with EGF (50 nM) were used as a positive control.
-luc and MEK5WT or MEK5AA plasmids for 24 h, then cells were serum starved for 8 h,
) for 18 h. Relative light units were measured and values were normalized to the total
tivity in cells transfected with mef2A-luc and MEK5WT accordingly. Results from nine
ere analyzed with a Student t-test and the level of signiﬁcance was set as Pb0.05 (*).
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Fig. 6. A) HepG2 cells were transfected with mef2A-luc and simultaneously co-
expressed (after transfection with the corresponding expressing plasmids) MEK5WT or
MEK5AA or MEK5DD and either Rab5WT or Rab5S34N for 24 h. Then cells were serum
starved for 8 h, and treated with HCVne particles for 18 h. Relative light units were
measured and values were normalized to the total protein amount. Results from eight
independent experiments performed in triplicates were analyzed with a Student t-test
and the level of signiﬁcance was set as Pb0.05 (*), Pb0.01 (**), Pb0.001 (***) B) Total
mRNAs were isolated at indicated time points from HepG2 cells transfected or not with
GFP-Rab5WT, GFP-Rab5S34N and incubated with HCVne or EGF as a positive control.
RT-PCR was performed with speciﬁc primers for mef2A (a), 28S (b).
1860 K. Katsarou et al. / Biochimica et Biophysica Acta 1813 (2011) 1854–1862have been proposed to activate this pathway such as EGF (epidermal
growth factor), TGFb (transforming growth factor-b), NGF (nerve
growth factor) and PDGF (platelet-derived growth factor) as well as
different oxidants and hyperosmolarity [12]. Furthermore, this
pathway has been found to be activated in different type of cancers,
including hepatocellular carcinoma, a state which is often observed in
HCV chronic patients [4,12,45]. To our knowledge this is the ﬁrst
report describing involvement of hepatitis C virus proteins in the
activation of ERK5 pathway.
HCV core structural and NS5A non structural proteins are known
to inﬂuence a great number of MAPK pathways [46–49], therefore,
they were initially chosen in this study in order to investigate if their
expression can provoke a potential induction of ERK5 phosphoryla-
tion. A range of assays was used, no activation of the pathway was
observed upon exposure of cells to either of these proteins. InFig. 7. ERK5 subcellular localization. Untreated Huh7 cells starved for 12 h (A), treated with
ﬁxed and immunostained with ERK5 antibody. Representative confocal sections are presencontrast, when cells of hepatic origin were challenged with HCV non-
enveloped particles (HCVne), a signiﬁcant phosphorylation of ERK5
protein was observed, with maximum activation after 30 min of
incubation at 37 °C. The signal was absent when heat-denatured
HCVne particles or a control fraction of the same density was used in
cells over the same time scale. This effect was shown to be speciﬁc as
the increase in HCVne particles quantity was followed by an ampliﬁed
signal. Furthermore, the particulate conformation seems to be
important as no activation was observed when soluble core protein
was used even at high concentrations.
It has been suggested that MEK5 protein acts as the major ERK5-
activating kinase, with MEKK3 being an upstream activating kinase
for MEK5 [41,50]. The catalytic domains of MEK5 and MEK1 (member
of the ERK1/2 pathway) show a 46% amino acid sequence identity,
making the use of MEK1/2 inhibitors possible, as no speciﬁc inhibitors
of the MEK5–ERK5 pathway exist [28]. Thus, to investigate the
involvement of MEK5 protein in HCVne-ERK5 pathway activation,
MEK1/2 inhibitors UO126 and PD98059 were used. Furthermore, lower
concentration of these inhibitors, generally used to block ERK1/2
pathway, had no effect in ERK5 pathway. This result provides evidence
that the observed ERK5 activation is not an effect of a cross-talk
between ERK1/2 and ERK5 pathways as it has been previously proposed
[51], but rather a direct ERK5 activation. However, the use of UO126
inhibitor at high concentration with an increased pretreatment time,
efﬁciently blocked ERK5 phosphorylation, providing evidence of the
involvement of MEK5 in the HCVne-ERK5 pathway activation. It is
important to note that the use of PD98059 at high concentrations failed
to inhibit the activation of the pathway. This phenomenon has already
been described [52] and is probably due to a different mode of action
of these inhibitors.
In addition HCVne particles were shown to activate a well known
downstream target of the ERK5 pathway,mef2. MEF2 proteins belong
to the MADS box (maintenance agamous deﬁcient serum-response
factor) transcription regulators family, with established roles in
skeletal–cardiac smooth muscle differentiation and neuronal survival,
as well as in gene regulation in response to mitogenic signaling and
hepatocellular carcinoma [53–56]. Furthermore, a relation of MEF2
protein with class II histone deacetylases (II HDACs) and histone
acetyl transferases (HATs) has been characterized [57]. Altered
histone acetylation is considered to inﬂuence regulation of gene
transcription and eventually carcinogenesis. It is tempting to
speculate that HCVne particles could inﬂuence this type of gene
deregulation via MEF2 protein.
However, themef2 gene has also been proposed to be regulated by
the p38-MAPK pathway [58,59]. The use of SB202190, a known p38
pathway inhibitor, inmef2-luc transfected cells was impossible in our
experimental conditions due to the high toxicity effects of this agent
(data not shown). Nevertheless, the activation observed by HCVne
particles was completely abolished when high concentrations of
UO126 inhibitor or overexpression of MEK5AA plasmid were used,
proving no p38 involvement and a direct activation of the MEK5–
ERK5–mef2 pathway.EGF (50nM) as a control (B) and incubated with HCVne particles for 30 min (C) were
ted.
MEK5
ERK5
?
?
???
mef2
HCVne
Early
endosome
Lysosome
Late
endosome
Fig. 8. Hypothetical model of ERK5 pathway activation by HCVne particles. HCVne particles most likely enter the cells by the clathrin-dependent pathway, although an alternative
entry pathway is not excluded [9]. By 30 min the MEK5–ERK5 pathway is induced, followed by mef2 activation.
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and themechanismof endocytosis is needed, data obtained in this study
by using the Rab5S34Nmutant combined with the observation that the
particulate form of core protein induces pathway activation, provide
strong evidence that this activation was sensitized by HCVne endocy-
tosis. It is noteworthy that HCV core in hepatocytes is capable of shifting
TGF-b responses from cytostatic effects to EMT development [60] and
ERK5 is considered to be a new component of hepatocyte response to
TGFb [34]. Furthermore extracellular HIV tat protein was previously
demonstrated to induce the production of high levels of TGF-b [61]
suggesting that HCVne particles can act in a similar way.
It has been proposed that ERK5 can shuttle between the cytoplasm
and the nucleus depending on the stimulation [37,62]. Althoughwe have
observed some nuclear translocation of ERK5 after HCVne incubation,
supportingdirectmef2 activation,we cannot exclude thepossibility for an
indirect activation of this transcription factor. As an example it was
recently reported that calcium is required for EGF-induced ERK5
activation [63] and a possible alteration of intracellular calcium levels
afterHCVneendocytosis cannotbeexcluded, aswell as inﬂuences causing
induction of cellular stresses such as H2O2 and ﬂuid shear stress [64,65].
In conclusion, data presented in this study provide evidence that
HCVne particles can speciﬁcally activate the MEK5–ERK5–mef2
pathway as summarized in Fig. 8. HCV nucleocapsids can be found
in signiﬁcant quantities in serum. HCV propagation although
progressed, is restricted to certain genotypes and moreover HCV
production of different forms of viral particles in cell culture is still
largely limited, begging the question of whether naturally occurring
HCVne particles can indeed be potent regulators of critical signaling
pathways. Additional information is required in order to clarify this
mechanism and to resolve the intriguing puzzle concerning the role of
HCVne particles as modulators of MAPK signaling.
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